Ayukawa Yasunori, Yasukawa Eisuke, Moriyama Yasuko, Ogino Yoichiro, Wada Hiroko, Atsuta Ikiru, Koyano Kiyoshi
Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Mar;107(3):336-42. doi: 10.1016/j.tripleo.2008.07.013. Epub 2008 Sep 17.
We investigated whether the local administration of simvastatin affected both the cellular events and the bone formation at surgically created bone defects in rat.
Simvastatin (or a vehicle) was injected into a rat bony defect for 3 consecutive days from the day of surgery. Five or ten days after the injection, new bone tissue was collected, and the gene expressions of bone-related proteins were examined. For the histomorphometry, new bone area was measured.
At day 5, the statin group demonstrated significantly larger new bone area. The number of tartrate-resistant acid phosphatase-positive multinucleated cells in the statin group was less than in the control group. In the statin group, the expressions of both alkaline phosphatase and bone morphogenetic protein 2 mRNA significantly increased. In contrast, the expression of cathepsin K was significantly suppressed in the statin group. Although the levels of both RANK and osteoprotegerin were not affected by statin, the expression of RANKL was depressed. At day 10, there were no significant differences among the groups in either histomorphometric or reverse-transcription polymerase chain reaction analyses.
New bone area increased under the influence of simvastatin; however, the effect did not continue when the administration was terminated. Osteoclast suppression may be the consequence of RANKL depression.
我们研究了辛伐他汀局部给药是否会影响大鼠手术造成的骨缺损处的细胞事件和骨形成。
从手术当天起,连续3天向大鼠骨缺损处注射辛伐他汀(或赋形剂)。注射后5天或10天,收集新骨组织,并检测骨相关蛋白的基因表达。进行组织形态计量学分析时,测量新骨面积。
在第5天,他汀类药物组的新骨面积明显更大。他汀类药物组中抗酒石酸酸性磷酸酶阳性多核细胞的数量少于对照组。在他汀类药物组中,碱性磷酸酶和骨形态发生蛋白2 mRNA的表达均显著增加。相比之下,他汀类药物组中组织蛋白酶K的表达受到显著抑制。尽管RANK和骨保护素的水平均不受他汀类药物影响,但RANKL的表达降低。在第10天,组织形态计量学分析或逆转录聚合酶链反应分析中,各组之间均无显著差异。
在辛伐他汀的影响下,新骨面积增加;然而,给药终止后,这种效果并未持续。破骨细胞抑制可能是RANKL降低的结果。